Scientists from UC Davis Center for Surgical Bioengineering, the MIND Institute and UC Berkeley’s Murthy Lab are developing ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Single-use systems streamline CGT manufacturing by reducing cleaning validation and enabling quick changeovers, essential for ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world applications in medicine and agriculture.

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to ...

A long-established drug with a diverse medical history is drawing new attention for its potential role in treating an ultra-rare and life-threatening genetic disorder. Early findings suggest that a me ...

A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...